Paragonix Technologies

The BAROguard lung preservation system. [Image courtesy of Paragonix Technologies]Paragonix Technologies announced today that it successfully completed the first-in-human case using its new donor lung preservation technology.

Waltham, Massachusetts-based Paragonix received FDA clearance for the BAROguard donor lung preservation system in August. It offers an alternative to the current practices. These practices see donor lungs preserved and transported from an inflated state between donor and recipient. Those current organ recovery techniques fail to reliably maintain and control inflation pressures.

The company designed it to combine its existing advanced hypothermic preservation technology with automated continuous and active airway pressure control. This ensures that the system maintains an optimal temperature range and a clinically recommended inflation pressure range. It maintains this for donor lungs throughout the journey from donor to recipient patient. Read more

Paragonix Technologies announced today that it opened its new corporate headquarters in Waltham, Massachusetts.

The organ transplant tech company says its expansion reflects continued growth and its commitment to serving clinicians and patients worldwide. Paragonix’s facility features state-of-the-art R&D laboratories and collaborative spaces. It aims to foster innovation and teamwork across departments in the evolving field of organ transplantation.

According to a news release, the 34,000-square-foot center serves as a consolidated hub of Paragonix’s diverse operations. The company highlighted its location in what it called “the vibrant technology corridor” of Greater Boston. Moving headquarters comes during a phase of accelerated growth for Paragonix, too.

The company said it designed the facility’s capacity to meet escalating customer demand and accommodate future expansion. Paragonix also plans to continue to grow it…

The BAROguard lung preservation system. [Image courtesy of Paragonix Technologies]Paragonix Technologies announced today that the FDA granted clearance for its next-generation BAROguard donor lung preservation system.

BAROguard combines Paragonix’s existing advanced hypothermic preservation technology with automated continuous and active airway pressure control. This ensures that the system maintains an optimal temperature range and a clinically recommended inflation pressure range. It maintains this for donor lungs throughout the journey from donor to recipient patient.

According to a news release, current practice sees donor lungs preserved and transported from an inflated state between donor and recipient. However, current organ recovery techniques fail to reliably maintain and control inflation pressures. Dr. Lisa Anderson, Paragonix president and CEO, said BAROguard addresses these issues with an automated, easy-to-use pressure management system.

Read more

[Image from Paragonix]Paragonix Technologies announced today that it secured $24 million in a Series B financing round.

Cambridge, Massachusetts-based Paragonix plans to use the funds to bolster its commercial footprint. That includes the ongoing extension of its clinical service offerings and inventory expansion. The company also plans to use funds to further advance its organ transplant innovations.

Signet Healthcare Partners led the Series B round.

“At Signet, we seek to invest in highly innovative and fast-growing healthcare companies,” said Signet managing director Ashley Friedman. “Paragonix has rapidly become a leader in the organ transplant market and is having a significant impact on the future of transplant medicine. We are impressed by their commercial and clinical achievements to date and are excited to partner with their dedicated and versatile team during the next phase of growth.”

About Paragonix Technologies’…

[Image from Paragonix]Paragonix Technologies announced today that it has preserved more than 2,000 donor organs for transport and transplantation.

Cambridge, Massachusetts-based Paragonix designed its devices to combine clinically proven, stable, hypothermic preservation technology with an extensive clinical support network with digital tools for complete control over the process of organ tracking, monitoring and reporting.

“We are humbled and grateful to be part of transplant patients’ path to a new life while honoring the selfless gift of donor patients with our technology,” Paragonix CEO Dr. Lisa Anderson said in a news release. “Our portfolio of advanced organ preservation and tracking systems provides a safe and effective way for donor organs to be preserved, tracked, and transported to their destination.”

The company said that, along with its milestone of 2,000 preserved, transported and tracked donor organs, its research partners ha…